| 2017 |
| 12/14 | 745 | 762 | 745 | 761 | +2.42% | 119,100 | 274億7265万 | +0.93% |
| 12/13 | 720 | 748 | 716 | 743 | +3.34% | 156,300 | 268億2284万 | -1.59% |
| 12/12 | 720 | 738 | 714 | 719 | -5.39% | 275,300 | 259億5642万 | -5.02% |
| 12/11 | 768 | 777 | 753 | 760 | -4.4% | 285,500 | 274億3655万 | +0.13% |
| 12/08 | 810 | 815 | 751 | 795 | +0.89% | 310,800 | 287億8万 | +4.61% |
| 12/08 | 8:00 MN-166のALSを適応とする臨床治験に関するポジティブなトップラインデータについてのお知らせ |
| 12/07 | 765 | 808 | 759 | 788 | +5.21% | 164,000 | 284億4737万 | +3.96% |
| 12/06 | 750 | 755 | 738 | 749 | +0.4% | 105,200 | 270億3944万 | -1.32% |
| 12/05 | 15:30 米国本社移転のお知らせ |
| 12/05 | 760 | 771 | 745 | 746 | -3.24% | 121,300 | 269億3114万 | -2.36% |
| 12/04 | 776 | 780 | 770 | 771 | -1.28% | 91,200 | 278億3366万 | +0.26% |
| 12/01 | 783 | 785 | 775 | 781 | 0% | 64,300 | 281億9467万 | +1.69% |
| 11/30 | 790 | 793 | 775 | 781 | -0.13% | 95,500 | 281億9467万 | +1.96% |
| 11/29 | 768 | 793 | 767 | 782 | +1.56% | 80,500 | 282億3077万 | +2.36% |
| 11/28 | 790 | 790 | 764 | 770 | -3.14% | 129,900 | 277億9756万 | +1.05% |
| 11/27 | 800 | 807 | 789 | 795 | -0.87% | 101,200 | 287億8万 | +4.61% |
| 11/24 | 800 | 812 | 789 | 802 | +1.01% | 180,200 | 289億5278万 | +5.94% |
| 11/22 | 762 | 807 | 760 | 794 | +4.2% | 269,900 | 286億6398万 | +5.31% |
| 11/21 | 763 | 772 | 756 | 762 | -0.39% | 102,000 | 275億875万 | +1.46% |
| 11/20 | 736 | 769 | 728 | 765 | +3.1% | 158,300 | 272億7672万 | +1.86% |
| 11/17 | 753 | 763 | 742 | 742 | +1.92% | 117,200 | 264億5664万 | -1.07% |
| 11/16 | 692 | 735 | 692 | 728 | +5.51% | 174,000 | 259億5746万 | -2.8% |
| 11/15 | 679 | 695 | 673 | 690 | +2.53% | 203,400 | 246億253万 | -7.88% |
| 11/14 | 692 | 700 | 671 | 673 | -3.17% | 187,000 | 239億9638万 | -10.27% |
| 11/13 | 722 | 722 | 695 | 695 | -4.53% | 220,400 | 247億8081万 | -7.58% |
| 11/10 | 15:30 ストックオプション(新株予約権)の発行に関するお知らせ |
| 11/10 | 15:30 新取締役就任に関するお知らせ |
| 11/10 | 729 | 745 | 717 | 728 | -1.49% | 195,100 | 259億5746万 | -3.32% |
| 11/10 | 8:00 MN-166のメタンフェタミン(覚醒剤)依存患者を対象とするバイオマーカー臨床治験開始のお知らせ |
| 11/09 | 770 | 772 | 730 | 739 | -5.01% | 276,500 | 263億4967万 | -2.12% |
| 11/08 | 770 | 779 | 761 | 778 | -0.26% | 162,000 | 277億4025万 | +2.91% |
| 11/07 | 792 | 792 | 768 | 780 | -1.39% | 201,200 | 278億1156万 | +3.31% |
| 11/06 | 773 | 821 | 770 | 791 | +2.46% | 472,500 | 282億377万 | +5.05% |
| 11/02 | 734 | 773 | 732 | 772 | +2.25% | 565,700 | 275億2631万 | +2.93% |
| 11/01 | 803 | 811 | 750 | 755 | -6.79% | 775,300 | 269億2016万 | +0.94% |
| 10/31 | 800 | 840 | 794 | 810 | -5.7% | 642,600 | 288億8124万 | +8.58% |
| 10/30 | 19:00 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験(SPRINT-MS)に関して学会発表内容のお知らせ |
| 10/30 | 904 | 923 | 810 | 859 | -3.37% | 1,627,300 | 306億2837万 | +15.61% |
| 10/27 | 769 | 889 | 757 | 889 | +20.3% | 2,695,300 | 316億9805万 | +20.95% |
| 10/26 | 19:00 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験に関して2つの主要評価項目(プライマリーエンドポイント)達成のお知らせ |
| 10/26 | 734 | 745 | 732 | 739 | +2.5% | 110,400 | 263億4967万 | +1.93% |
| 10/25 | 740 | 746 | 720 | 721 | -3.35% | 196,700 | 257億787万 | +0.14% |
| 10/24 | 740 | 747 | 732 | 746 | +1.5% | 132,300 | 265億9926万 | +4.19% |
| 10/24 | 8:30 2017年12月期第3四半期決算短信〔米国基準〕(連結) |
| 10/23 | 713 | 744 | 713 | 735 | +3.38% | 198,700 | 262億705万 | +3.38% |
| 10/20 | 705 | 712 | 695 | 711 | +0.14% | 121,700 | 249億9418万 | +0.71% |
| 10/19 | 711 | 719 | 701 | 710 | -2.2% | 160,400 | 249億5903万 | +1.14% |
| 10/18 | 15:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ |
| 10/18 | 739 | 741 | 716 | 726 | -0.27% | 100,600 | 255億2148万 | +4.16% |
| 10/17 | 750 | 754 | 728 | 728 | -3.58% | 138,500 | 255億9179万 | +5.35% |
| 10/16 | 751 | 758 | 738 | 755 | +1.21% | 131,400 | 265億4094万 | +10.06% |
| 10/13 | 746 | 760 | 736 | 746 | +2.33% | 211,400 | 262億2456万 | +9.87% |
| 10/12 | 720 | 742 | 720 | 729 | +2.1% | 196,800 | 256億2694万 | +8.48% |
| 10/11 | 726 | 731 | 711 | 714 | -0.7% | 108,300 | 250億9964万 | +7.37% |
| 10/10 | 718 | 720 | 704 | 719 | -0.96% | 136,000 | 252億7541万 | +8.94% |
| 10/06 | 712 | 744 | 687 | 726 | +1.82% | 325,800 | 255億2148万 | +10.84% |
| 10/05 | 775 | 777 | 682 | 713 | -8.12% | 617,600 | 250億6449万 | +9.69% |
| 10/04 | 775 | 783 | 766 | 776 | +0.39% | 299,400 | 272億7916万 | +20.31% |
| 10/03 | 750 | 773 | 745 | 773 | +3.76% | 399,700 | 271億7370万 | +21.16% |
| 10/03 | 8:00 有価証券の募集に係る発行登録の承認に関するお知らせ |
| 10/02 | 15:30 従業員株式購入プランの実施(新株発行)に関するお知らせ |
| 10/02 | 736 | 745 | 730 | 745 | +2.34% | 271,200 | 261億8940万 | +18.07% |
| 09/29 | 720 | 735 | 705 | 728 | -0.27% | 163,300 | 255億9179万 | +16.67% |
| 09/28 | 733 | 739 | 717 | 730 | +2.24% | 162,100 | 256億6210万 | +18.12% |
| 09/27 | 698 | 716 | 696 | 714 | +1.42% | 165,800 | 250億9964万 | +16.86% |
| 09/26 | 711 | 740 | 686 | 704 | -3.16% | 540,300 | 247億4811万 | +16.36% |
| 09/25 | 702 | 728 | 690 | 727 | +7.39% | 537,400 | 255億5664万 | +21.37% |
| 09/22 | 642 | 685 | 642 | 677 | +7.63% | 446,600 | 237億9896万 | +14.36% |
| 09/21 | 629 | 632 | 602 | 629 | +1.62% | 180,100 | 221億1159万 | +6.97% |
| 09/20 | 639 | 639 | 619 | 619 | -0.48% | 276,600 | 217億750万 | +5.99% |
| 09/19 | 19:00 MN-166のメタンフェタミン(覚醒剤)依存症を適応とするフェーズ2臨床治験の患者登録完了のお知らせ |
| 09/19 | 619 | 624 | 612 | 622 | +2.3% | 83,200 | 218億1270万 | +7.06% |
| 09/15 | 610 | 625 | 588 | 608 | -3.49% | 229,300 | 213億2174万 | +5.74% |
| 09/14 | 593 | 633 | 590 | 630 | +6.06% | 320,100 | 220億9325万 | +10.33% |
| 09/13 | 596 | 600 | 593 | 594 | -0.17% | 75,000 | 208億3078万 | +4.76% |
| 09/12 | 586 | 596 | 584 | 595 | +1.71% | 49,400 | 208億6585万 | +5.5% |
| 09/11 | 584 | 590 | 580 | 585 | -0.17% | 39,200 | 205億1516万 | +4.09% |
| 09/08 | 584 | 589 | 579 | 586 | +0.34% | 46,800 | 205億5023万 | +4.46% |
| 09/07 | 589 | 593 | 579 | 584 | +4.1% | 60,300 | 204億8009万 | +4.29% |
| 09/06 | 543 | 576 | 543 | 561 | -1.06% | 61,000 | 196億7351万 | +0.18% |
| 09/05 | 591 | 594 | 562 | 567 | -3.9% | 61,000 | 198億8393万 | +1.25% |
| 09/04 | 591 | 597 | 589 | 590 | -1.17% | 36,800 | 206億9051万 | +5.36% |
| 09/01 | 592 | 600 | 592 | 597 | -0.5% | 30,400 | 209億3599万 | +6.61% |
| 08/31 | 599 | 600 | 591 | 600 | +1.01% | 53,100 | 210億4119万 | +7.14% |
| 08/30 | 596 | 597 | 589 | 594 | -0.17% | 25,600 | 208億3078万 | +6.26% |
| 08/29 | 587 | 595 | 580 | 595 | +0.34% | 38,600 | 208億6585万 | +6.44% |
| 08/28 | 585 | 595 | 584 | 593 | +3.13% | 116,100 | 207億9571万 | +5.89% |
| 08/25 | 575 | 583 | 563 | 575 | +0.7% | 118,800 | 201億6448万 | +2.68% |
| 08/24 | 563 | 571 | 555 | 571 | +0.88% | 45,600 | 200億2420万 | +1.96% |
| 08/23 | 558 | 573 | 558 | 566 | +1.98% | 73,600 | 198億4886万 | +1.07% |
| 08/22 | 551 | 562 | 546 | 555 | +0.18% | 40,300 | 194億6310万 | -1.07% |
| 08/21 | 560 | 565 | 551 | 554 | -1.07% | 58,900 | 194億2803万 | -1.42% |
| 08/18 | 536 | 562 | 530 | 560 | +0.36% | 76,500 | 196億1043万 | -0.53% |
| 08/17 | 554 | 562 | 553 | 558 | +1.45% | 44,800 | 195億4040万 | -1.06% |
| 08/16 | 539 | 558 | 525 | 550 | +3.97% | 94,600 | 192億6025万 | -2.65% |
| 08/15 | 492 | 529 | 492 | 529 | +8.85% | 112,000 | 185億2486万 | -6.54% |
| 08/14 | 495 | 498 | 480 | 486 | -3.76% | 149,400 | 170億1905万 | -14.44% |
| 08/10 | 518 | 518 | 497 | 505 | -2.51% | 145,400 | 176億8441万 | -11.71% |
| 08/09 | 525 | 526 | 513 | 518 | -2.08% | 85,400 | 181億3965万 | -10.07% |
| 08/08 | 531 | 531 | 517 | 529 | -2.22% | 122,100 | 185億2486万 | -8.48% |
| 08/07 | 556 | 556 | 540 | 541 | -3.91% | 105,400 | 189億4508万 | -6.88% |
| 08/04 | 559 | 563 | 558 | 563 | -0.71% | 44,900 | 197億1549万 | -3.43% |
| 08/03 | 569 | 570 | 560 | 567 | -1.05% | 81,000 | 198億5556万 | -2.91% |
| 08/02 | 572 | 576 | 571 | 573 | +0.53% | 24,200 | 200億6568万 | -2.22% |
| 08/01 | 583 | 583 | 570 | 570 | -0.52% | 92,000 | 199億6062万 | -2.9% |
| 07/31 | 585 | 585 | 571 | 573 | -1.38% | 74,300 | 200億6568万 | -2.55% |
| 07/28 | 580 | 583 | 577 | 581 | -0.85% | 42,200 | 203億4582万 | -1.53% |
| 07/27 | 10:00 2017年12月期第2四半期決算説明会資料 |
| 07/27 | 583 | 588 | 581 | 586 | -0.85% | 49,900 | 205億2092万 | -0.85% |
| 07/27 | 8:30 2017年12月期第2四半期決算短信〔米国基準〕(連結) |
| 07/26 | 590 | 594 | 586 | 591 | -0.84% | 27,700 | 206億9601万 | 0% |
| 07/25 | 600 | 600 | 591 | 596 | -0.67% | 35,900 | 208億7110万 | +0.85% |
| 07/24 | 599 | 601 | 593 | 600 | +0.33% | 30,600 | 210億1118万 | +1.35% |
| 07/21 | 586 | 599 | 578 | 598 | +3.82% | 111,500 | 209億4114万 | +1.01% |
| 07/19 | 15:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ |
